Short answer
Nkarta, Inc. (NKTX) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$22M
- +23.4% YoY · +5.5% QoQ
- EPS (diluted)
- −$0.30
- +21.1% YoY · +3.2% QoQ
Source: XBRL data from the Nkarta, Inc. (NKTX) Q3 2025 10-Q on SEC EDGAR. USD.
Nkarta, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product-sales revenue; continued significant losses and no profitability
- Additional capital required, with potential dilution or operational restrictions
- NKX019 clinical success and CAR NK-cell platform as primary business dependencies
- Manufacturing complexity, sole-supplier reliance, and facility approval delays as development risks
- Clinical enrollment, safety, efficacy, and regulatory uncertainties creating near-term headwinds
Risk Factors
- Newly flagged long-lived-asset impairment risk triggered by sustained stock-price decline and market capitalization below net asset value
- Losses $76.7 million for nine months ended September 30, 2025 and accumulated deficit $620.9 million
- Additional financing risk with $316.5 million cash, restricted cash, equivalents and investments as of September 30, 2025
- CAR NK-cell regulatory risk from no approved NK-based cell therapy or autoimmune cell therapy precedent
- Competitive risk from deprioritized hematologic-malignancy programs after unfavorable data and a highly competitive B-cell malignancy market
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nkarta, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.